[The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease].
18 patients with early parkinsonism presenting in different clinical forms have undergone 3-month treatment with umex (10 mg/day). The response was evaluated in accordance with unified scale assessing the condition, motor tests, personal and reactive anxiety. Umex brought a significant improvement of motor activity, prolonged the effect of a single dose of DOPA-containing medication, reduced anxiety. Side effects were insignificant.
Fedorova
N V
NV
Glozman
Zh M
ZhM
Saltykova
N M
NM
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D012642:Selegiline; D004295:Dihydroxyphenylalanine
Effektivnost' lecheniia iumekssom bol'nykh parkinsonizmom v nachal'noĭ stadii zabolevaniia.